AI Article Synopsis
- Kaposi's sarcoma (KS) is a soft tissue lesion linked to HHV-8 infection, often seen in immunocompromised patients, especially those with AIDS, and has a high mortality rate.
- A case report details a patient with AIDS-KS who relapsed after initial chemotherapy, but achieved complete remission with a PD-1 inhibitor, indicating its effectiveness in treatment.
- The PD-1 inhibitor was well-tolerated, improved the patient's immune system, and suggests a promising approach for managing AIDS-KS.
Article Abstract
Kaposi's sarcoma (KS) is a soft tissue lesion that resembles a hyperpigmented angiosarcoma and is typically associated with human herpesvirus 8 (HHV-8) infection. It is most frequently observed in immunocompromised patients, particularly those with AIDS, and is also referred to as HIV-associated Kaposi's sarcoma (AIDS-KS). The disease progresses rapidly, is challenging to manage, and has a high mortality rate. This case report presents a patient with AIDS-KS who experienced relapse after chemotherapy with anthracyclines. Subsequent chemotherapy with the same method had no significant effect. However, complete remission was achieved after the addition of a programmed cell death protein 1(PD-1) inhibitor, as confirmed by pathological biopsy. The PD-1 inhibitor was well-tolerated and had few adverse effects. It also helped to improve the immune reconstitution of the patient. The report highlights the remarkable efficacy of the PD-1 inhibitor in treating AIDS-KS. This provides case support for PD-1 inhibitors for AIDS-KS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695220 | PMC |
| http://dx.doi.org/10.3389/fonc.2024.1462381 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Strict regulation of type I interferons (IFN) is vital for balancing tissue damage and immunity against infections. We previously found that during Kaposi's sarcoma-associated herpesvirus infection, IFN induction was limited to a small percentage of infected B cells. This heterogeneity was not explained by viral gene expression.
View Article and Find Full Text PDFObjective: Elevated blood pressure (BP), even at prehypertensive levels, increases cardiovascular disease risk among people with HIV (PWH); yet international guidelines in low-income countries recommend treatment initiation at BP at least 140/90 mmHg. We determined the efficacy, feasibility, and acceptability of treating prehypertension in PWH in Haiti.
Design: An unblinded randomized clinical trial (enrolled April 2021-March 2022) with 12-month follow-up.
Successful treatment of recurrent refractory Kaposi's sarcoma in AIDS: a case report.
Front Oncol
December 2024
The Second Infectious Disease Department, Xixi Hospital of Hangzhou, Hangzhou, China.
Article Synopsis
- Kaposi's sarcoma (KS) is a soft tissue lesion linked to HHV-8 infection, often seen in immunocompromised patients, especially those with AIDS, and has a high mortality rate.
- A case report details a patient with AIDS-KS who relapsed after initial chemotherapy, but achieved complete remission with a PD-1 inhibitor, indicating its effectiveness in treatment.
- The PD-1 inhibitor was well-tolerated, improved the patient's immune system, and suggests a promising approach for managing AIDS-KS.
[Pulmonary Kaposi sarcoma after lung transplantation: a case report and literature review].
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
Department of Organ Transplantation, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou510120, China.
To investigate the clinical features, diagnosis, and treatment of pulmonary Kaposi sarcoma (KS) after lung transplantation. A case of pulmonary KS after bilateral lung transplantation was retrospectively analyzed. Two key words "Kaposi sarcoma" and "lung transplant*" were used to search for relevant literature in SinoMed, Wanfang Data, CNKI, PubMed, Embase, Cochrane Library and Web of Science, with a cut-off date of July 31, 2024.
View Article and Find Full Text PDFClinical Management of Human Herpesvirus-8 related illnesses in solid organ transplant recipients.
J Infect
January 2025
Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK; Centre for Immunology and Vaccinology, Department of Infectious Diseases, Imperial College, London, UK. Electronic address:
In solid organ transplant recipients (SOTRs), the oncogenic virus human herpesvirus-8 (HHV-8) also named Kaposi sarcoma herpesvirus (KSHV) causes four clinical diseases: Kaposi Sarcoma, Primary Effusion Lymphoma, Multicentric Castleman Disease (MCD), and KSHV inflammatory cytokine syndrome (KICS). This review outlines these clinical scenarios and discusses their management. Although HHV8 related disease in SOTR was first described more than three decades ago, there is a lack of data on treatment so much of the guidance is based on evidence in other immunodeficient patients, particularly people living with HIV.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!